DDInter596 DDInter1835
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
Doxorubicin {u} (Compound) treats {v} (Disease) peripheral nervous system neoplasm
peripheral nervous system neoplasm {u} (Disease) is treated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) upregulates {v} (Gene) ALDH5A1
ALDH5A1 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) ABCC10
ABCC10 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) binds {v} (Gene) NOS3
NOS3 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Topoisomerase Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Topotecan
Doxorubicin {u} (Compound) downregulates {v} (Gene) CCNF
CCNF {u} (Gene) is downregulated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Topotecan
Doxorubicin {u} (Compound) causes {v} (Side Effect) Mucosal inflammation
Mucosal inflammation {u} (Side Effect) is caused by {v} (Compound) Topotecan
Doxorubicin (Compound) treats peripheral nervous system neoplasm (Disease) and peripheral nervous system neoplasm (Disease) is treated by Topotecan (Compound)
Doxorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Topotecan (Compound)
Doxorubicin (Compound) upregulates ALDH5A1 (Gene) and ALDH5A1 (Gene) is upregulated by Topotecan (Compound)
Doxorubicin (Compound) binds ABCC10 (Gene) and Doxorubicin (Compound) upregulates ABCC10 (Gene) and ABCC10 (Gene) is upregulated by Topotecan (Compound)
Doxorubicin (Compound) binds NOS3 (Gene) and NOS3 (Gene) is upregulated by Topotecan (Compound)
Doxorubicin (Compound) downregulates IER3 (Gene) and IER3 (Gene) is upregulated by Topotecan (Compound)
Doxorubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class) and Topoisomerase Inhibitors (Pharmacologic Class) includes Topotecan (Compound)
Doxorubicin (Compound) downregulates CCNF (Gene) and CCNF (Gene) is downregulated by Topotecan (Compound)
Doxorubicin (Compound) binds TOP2A (Gene) and Doxorubicin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is downregulated by Topotecan (Compound)
Doxorubicin (Compound) causes Mucosal inflammation (Side Effect) and Mucosal inflammation (Side Effect) is caused by Topotecan (Compound)